Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 21.30% and Operating profit at -0.99% over the last 5 years
2
With a growth in Net Sales of 26.33%, the company declared Very Positive results in Mar 26
3
With ROE of 6.17%, it has a fair valuation with a 1.71 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,620 Million (Mid Cap)
28.00
NA
0.00%
-0.45
6.17%
1.71
Revenue and Profits:
Net Sales:
236 Million
(Quarterly Results - Mar 2026)
Net Profit:
46 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.84%
0%
7.84%
6 Months
-19.19%
0%
-19.19%
1 Year
-25.16%
0%
-25.16%
2 Years
18.8%
0%
18.8%
3 Years
-27.95%
0%
-27.95%
4 Years
-74.88%
0%
-74.88%
5 Years
0%
0%
0.0%
ACROBiosystems Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
21.30%
EBIT Growth (5y)
-0.99%
EBIT to Interest (avg)
48.47
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.66
Sales to Capital Employed (avg)
0.25
Tax Ratio
4.17%
Dividend Payout Ratio
60.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.75%
ROE (avg)
6.17%
Valuation key factors
Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.71
EV to EBIT
28.60
EV to EBITDA
18.44
EV to Capital Employed
2.28
EV to Sales
3.84
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
7.99%
ROE (Latest)
6.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
235.60
186.50
26.33%
Operating Profit (PBDIT) excl Other Income
44.40
54.60
-18.68%
Interest
0.40
2.10
-80.95%
Exceptional Items
-0.50
0.00
Consolidate Net Profit
46.30
40.30
14.89%
Operating Profit Margin (Excl OI)
188.70%
172.60%
1.61%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 26.33% vs 27.74% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 14.89% vs 38.01% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
836.70
644.10
29.90%
Operating Profit (PBDIT) excl Other Income
203.50
131.00
55.34%
Interest
5.50
5.70
-3.51%
Exceptional Items
4.40
-0.00
Consolidate Net Profit
164.80
120.00
37.33%
Operating Profit Margin (Excl OI)
137.90%
91.20%
4.67%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 29.90% vs 18.62% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 37.33% vs -18.70% in Dec 2024
About ACROBiosystems Co., Ltd. 
ACROBiosystems Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






